. Author manuscript; available in PMC: 2019 Jan 1.

Published in final edited form as: Alzheimers Dement. 2017 Jul 22;14(1):43–53. doi: 10.1016/j.jalz.2017.06.2268

Table 1.

Baseline demographics and region volumes for participants included in the longitudinal analysis

Demographics	Noncarriers (NC)	Presymptomatic mutation carriers (preMut+)	Questionably or mildly symptomatic mutation carriers (qMut+)	Overtly symptomatic mutation carriers (sMut+)
N	28	24	18	24
Age, years (SD)	41.0 (8.4)	37.7 (10.1)	39.1 (10.2)	48.6 (8.2)^§
Sex, F/M	17/11	16/8	11/7	10/14
APOE status, No. (%)^*	6/28 (21%)	7/24 (29%)	6/18 (33%)	7/24 (29%)
Estimated years from expected symptom onset (EYO), years (SD)^†	−5.52 (8.62)	−8.05 (8.38)	−4.19 (5.76)	4.01 (6.46)^§
TIV, mL (SD)	1374 (129)	1373 (142)	1416 (124)	1483 (164)^§
Brain volume, mL (95% CI)^‡	1178 (1163, 1194)	1182 (1162, 1201)	1163 (1142, 1184)	1055 (1028, 1081)^§
Ventricular volume, mL (95% CI)^‡	15.2 (13.0, 17.46)	15.4 (12.5, 18.3)	20.0 (15.9, 24.0)^§	34.3 (28.5, 40.1)^§
Left hippocampal volume, mL (95% CI)^‡	3.01 (2.91, 3.10)	2.90 (2.79, 3.00)	2.73 (2.62, 2.84)^§	2.45 (2.28, 2.61)^§
Right hippocampal volume, mL (95% CI)^‡	3.08 (2.99, 3.17)	2.93 (2.82, 3.01)^§	2.76 (2.63, 2.89)^§	2.55 (2.37, 2.73)^§

Abbreviations: APOE, apolipoprotein E; TIV, total intracranial volume; SD, standard deviation; CI, confidence interval.

Number (%) with APOE genotype 24, 34, or 44.

^†

A negative value of EYO indicates that a participant joined the study before their expected age of onset, based on parental age at onset; EYO values for noncarriers are only indicative; EYO values for overtly symptomatic mutation carriers do not reflect clinically determined actual age of onset.

^‡

Regional volumes were standardized to the mean TIV using a linear regression model.

^§

P <.05 versus NC.